ENA carcinoma is a malignant tumour of the epithelium, the tissue lining the skin, mucous membranes and gland ducts. Many people first meet the word on a laboratory form, not from a doctor; it sounds more frightening than cancer, yet it simply names the most common form of cancer.
This page explains how a carcinoma differs from other tumours, its common subtypes, what a German hospital does first with the slides and how the plan is built. The exact approach depends on the organ; individual cancers are covered under cancer treatment in Germany.
What a carcinoma is, and what it is not
Carcinoma, a tumour of the epithelium, is the most common type of cancer: eight or nine in every ten cancer cases are carcinomas. The epithelium is a border tissue covering the body and lining its organs; its cells renew constantly, and the more often a tissue’s cells divide, the higher its cancer risk. Hence the familiar names: lung, stomach, breast and prostate cancers are usually carcinomas.
Not every malignant tumour is a carcinoma. A sarcoma grows from connective tissue — bone, muscle, fat — and has its own page on sarcoma treatment in Germany. Leukaemia and lymphoma arise from blood and lymphatic cells. These are different diseases with different protocols, not nuances of wording, so a German pathologist first confirms the tissue of origin.
The commonest subtypes are adenocarcinoma, from glandular epithelium; squamous cell carcinoma, from the flat epithelium of skin and mucous membranes; urothelial carcinoma of the bladder; and hepatocellular carcinoma of the liver. Basal cell carcinoma arises in the skin’s lowest layer (see basal cell carcinoma treatment in Germany). Carcinoma in situ is different: its cells have not crossed the basement membrane, the thin sheet beneath the epithelium, so they cannot reach blood vessels and do not yet spread. It is usually treated locally, by removal and sometimes radiotherapy, before it can become invasive.
Where carcinoma treatment in Germany actually begins
Carcinoma treatment in Germany begins with a second reading of the histology. The German pathologist asks for the slides and paraffin blocks — tissue set in wax — rather than the report, cuts fresh sections and confirms or changes the diagnosis. Disagreements over subtype and grade do happen, and serious ones change the treatment, not just the wording.
Next comes immunohistochemistry: antibody stains showing proteins on and inside the tumour cell — hormone receptors, HER2, PD-L1 and, when the tumour’s starting point is unclear, markers of tissue origin. Alongside it, molecular testing sequences the tumour’s DNA for gene changes that targeted drugs act on.
Staging follows, by the TNM system: T for tumour size and growth into nearby tissue, N for lymph nodes, M for distant metastases; CT, MRI and, where needed, PET-CT map the spread. The Krebsinformationsdienst of the German Cancer Research Center explains, in German, how to read these codes and the grade.
The tumour board decides, not one doctor
The plan is signed off by a tumour board (Tumorboard): the surgeon, medical oncologist, radiation oncologist, pathologist and radiologist review the images, histology and history together, and none of them prescribes alone. The result is a written plan, the board’s minutes; they go into the medical record, the recommendations are explained to the patient, who is entitled to a copy.
A centre certified by the German Cancer Society (DKG) passes a yearly external audit of checkable requirements: patients treated per year for its tumour type, board membership, record-keeping. A Comprehensive Cancer Center (CCC) is a university hospital’s cancer centre combining treatment with clinical research, selected and funded by the charity Deutsche Krebshilfe after international expert review. Both labels mean inspection, not marketing; see cancer hospitals in Germany.
Surgery, radiotherapy, drugs
Carcinoma is treated with surgery, radiotherapy and drugs, often combined. While a carcinoma is confined to its organ, surgery is the mainstay: the tumour is removed with a margin of healthy tissue that the pathologist checks, if needed during the operation, on a frozen section. Whether the organ can be kept depends on position and spread, not preference.
Radiotherapy can be the main treatment: for some squamous cell carcinomas, radiation, often with chemotherapy, replaces surgery. It also follows surgery to destroy residual cells and eases symptoms of metastases, such as bone pain. Proton therapy is discussed when the tumour lies against a sensitive structure such as the optic nerve; for many carcinomas, its benefit over standard radiotherapy remains under study.
Drug treatment means chemotherapy, targeted agents matched to the mutation found, and immunotherapy where biomarkers such as PD-L1 fit; see cancer immunotherapy in Germany. The choice follows the subtype and molecular profile, not the word carcinoma: lung and prostate adenocarcinomas need different drugs. No regimen promises an outcome in advance; the response is assessed as treatment goes on.
Frequently asked questions
Is a carcinoma the same as cancer?
Yes: a carcinoma is a cancer, a malignant tumour of the epithelium. The word says nothing about stage or outlook; it only names the tissue of origin. Treatment depends on what the report adds: the subtype, grade, TNM stage, immunohistochemistry and molecular results.
What does “poorly differentiated carcinoma” mean?
It means the tumour cells bear little resemblance to the healthy tissue they came from. Reports give the grade as G plus a number: the higher the number, the less differentiated the cells and the more malignant the tumour. As the grade shapes treatment, it is rechecked when the slides are re-read.
What if the primary site of a carcinoma cannot be found?
Then the diagnosis is CUP syndrome, for cancer of unknown primary: metastases are present, but their starting tumour cannot be found. Immunohistochemistry matters most here, as markers of tissue origin suggest which organ the tumour may have come from. The tumour board chooses treatment on that basis and by where the metastases are.
How AlenMed arranges treatment
AlenMed starts with the records: discharge summaries, the histology report, the slides and blocks for re-reading, sent separately, and imaging in DICOM. We translate them, pass them to the oncologists, obtain a written answer on what is confirmed and what is proposed, and ask the hospital for a preliminary estimate with a visa invitation letter.
AlenMed has 86 partner hospitals in 38 cities and 345 doctors; the company office is in Munich. For carcinoma we work through certified cancer centres and university hospitals nationwide. A coordinator meets the patient, interprets at appointments and collects the discharge summary, the pathology report and the follow-up plan.
This material is for information only and is not an offer. Treatment tactics are decided by a doctor at a face-to-face examination.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
